The V-set and Immunoglobulin Domain Containing (VSIG) family is a group of proteins characterized by the presence of V-set and immunoglobulin (Ig) domains. These domains are typically found in molecules involved in immune system functioning and cell adhesion. This family is currently comprised of eight members, including VSIG1, VSIG2, VSIG3, VSIG4, VSIG8, VSIG9, VSIG10, and VSIG10 L, which are all type I transmembrane proteins. Members of the VSIG family are predominantly expressed in the immune system and various epithelial tissues, suggesting a role in immune responses and epithelial cell interactions. The function of VSIG proteins often involves cell-cell adhesion, signaling, and modulation of immune responses, although the specific roles can vary among different family members. In terms of signaling, VSIG proteins are known to participate in a variety of pathways, including those that regulate cell proliferation, differentiation, and apoptosis, particularly in the context of immune and epithelial cells. Furthermore, some VSIG family members have been implicated in the development and progression of certain cancers, indicating their potential as targets or biomarkers in oncology.
Targeting V-set and Immunoglobulin Domain Containing (VSIG) proteins using small molecules can provide valuable insights into the mechanistic aspects of T-cell responses and immune suppressive microenvironments. VSIG proteins are implicated in immune cell interactions and signaling pathways that are crucial for the regulation of T-cell activity and immune tolerance. By disrupting or inhibiting VSIG proteins, researchers can observe changes in T-cell behavior, helping to elucidate their role in immune activation and suppression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
A potent inhibitor of both CHK1 and CHK2, used in preclinical studies for cancer. Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor, could interfere with VSIG-related MAPK/ERK signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, potentially affecting VSIG-related stress response pathways. | ||||||
LY2606368 | 1234015-52-1 | sc-507521 sc-507521A sc-507521B sc-507521C sc-507521D sc-507521E | 5 mg 10 mg 25 mg 100 mg 1 g 10 g | $176.00 $300.00 $500.00 $1900.00 $8000.00 $25000.00 | ||
A selective CHK1 inhibitor, being investigated in clinical trials for various types. Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, could modify VSIG-related inflammatory response pathways. | ||||||
PF 477736 | 952021-60-2 | sc-362781 sc-362781A | 5 mg 25 mg | $115.00 $431.00 | ||
A potent and selective CHK1 inhibitor Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role. | ||||||
SCH 900776 | 891494-63-6 | sc-364611 sc-364611A | 5 mg 10 mg | $255.00 $338.00 | ||
A selective CHK1 inhibitor, has been investigated in clinical trials Checkpoint Kinase (CHK) Inhibitors potentially affecting cell cycle control mechanisms in which VSIG proteins might play a role. | ||||||